We are live on ! Find out more
NVIV

InVivo Therapeutics Holdings Corp

Delisted

NVIV was delisted on the 12th of February, 2024.

28 hedge funds and large institutions have $3.04M invested in InVivo Therapeutics Holdings Corp in 2017 Q4 according to their latest regulatory filings, with 2 funds opening new positions, 5 increasing their positions, 7 reducing their positions, and 7 closing their positions.

New
Increased
Maintained
Reduced
Closed

15% less funds holding

Funds holding: 3328 (-5)

29% less repeat investments, than reductions

Existing positions increased: 5 | Existing positions reduced: 7

53% less capital invested

Capital invested by funds: $6.42M → $3.04M (-$3.38M)

71% less first-time investments, than exits

New positions opened: 2 | Existing positions closed: 7

100% less call options, than puts

Call options by funds: $0 | Put options by funds: $3K

Holders
28
Holders Change
-5
Holders Change %
-15.15%
% of All Funds
0.64%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
2
Increased
5
Reduced
7
Closed
7
Calls
Puts
$3K
Net Calls
-$3K
Net Calls Change
+$22K

NVIV Hedge Fund Activity: Q4 2017 in Review

28 of the 4,409 institutional investors tracked by Wall St. Rank reported a position in InVivo Therapeutics Holdings Corp (NVIV) for Q4 2017, worth a combined $3.04M — down 53% from $6.42M a quarter earlier.

Sellers outnumbered buyers: 7 funds closed out of NVIV and 2 opened new positions — a net loss of 5 holders — while 7 trimmed existing stakes and 5 added.

The largest buyer was IMS Capital Management, adding an estimated $162K. The largest seller was Welch & Forbes, cutting an estimated $324K.

  • 28 institutional investors held InVivo Therapeutics Holdings Corp (NVIV) as of Q4 2017, down from 33 in Q3 2017.
  • Funds reported $3.04M of InVivo Therapeutics Holdings Corp stock for Q4 2017, down 53% quarter-over-quarter.
  • 2 funds opened new InVivo Therapeutics Holdings Corp positions in Q4 2017 and 7 closed out, a net change of -5 holders.
  • The largest InVivo Therapeutics Holdings Corp buyer in Q4 2017 was IMS Capital Management, an estimated $162K added.
  • The largest InVivo Therapeutics Holdings Corp seller in Q4 2017 was Welch & Forbes, an estimated $324K sold.

Based on aggregated 13F filings for Q4 2017.